The Adhesys sealants are based on a unique polyurethane technology, for which Adhesys Medical owns all patents. The patents allow for fine-tuning of various product characteristics, such as curing time, degradation time and viscosity, based on which entirely new sealants for different uses can be developed.
VIVO has shown to be effective in a variety of different settings. Moreover, its capacity to rapidly stop bleeding makes it suitable for use in emergency and/or military applications. Due to the adjustability of the adhesive’s properties, it can be tailored to the requirements of different indications, providing for use of the technology in a great variety of application areas.
- Targeted Drug Delivery
- Trauma and Emergency Application
- Femoral Artery and Vascular Access Closure
- Minimally Invasive Application
- Hernia Repair
Targeted Drug Delivery
Not only effectively sealing a wound in a high-bleeding situation, but also bringing an active pharmaceutical ingredient (API) such as an antibiotic to the wound site and ensuring it remains at the intended site for long enough for the active ingredient to be released, is an increasingly sought after application. The use of VIVO in conjunction with an active ingredient would enable the direct application of an API to the wound surface and would ensure that it remains at the intended site. The spreader tip of the device allows for a targeted application and the high viscosity ensures that it remains in place and isn’t washed away by high blood loss. Furthermore, the product’s biodegradability, viscosity and setting time can be fine-tuned to the requirements of specific applications.
Trauma and Emergency Application
Due to its fast curing-time, VIVO is optimally suited for use in trauma and emergency situations. Its hydrophilic nature causes it to polymerize even faster in bleeding situations, where it can seal wounds and stop bleeding within seconds. It comes ready-to-use and has no special storage requirements, making it optimal for use in emergency situations or on the battlefield. After application, the wounded can be transported to a site of treatment, where the glue can be easily removed for wound care.
Femoral Artery and Vascular Access Closure
Currently, only insufficient devices for femoral artery closure after cardiothoracic procedures are available. With the development of a device for use in a minimally invasive setting, the adhesive’s high strength and quick sealing can be used to achieve quick femoral artery and vascular access closure.
With minimally invasive procedures becoming more and more common and thus the challenges related to the closing of incisions from minimally invasive surgery becoming more frequent, solutions to close this medical gap are urgently needed. The outstanding features of the Adhesys technology may allow for its use in a minimally invasive setting, for instance to stop punctual bleeding and to seal arterial incisions. Initial proof of concept tests have shown the usability of VIVO in a catheter application.
Mesh fixation during hernia repair is currently performed with staples and sutures, which impair movement and can cause nerve damage and inflammation. Currently used adhesives for hernia repair are commonly based on Cyanoacrylate. Cyanoacrylate glues however do not work in a wet environment. In contrast, due to its usability in a wet space, full biocompatibility and biodegradability, the VIVO technology meets the requirements for mesh fixation during hernia repair.
Pancreatic cancer is the 4th most common cause of death by cancer1, with around 330 000 deaths per year worldwide2. Pancreatic fistula formation after pancreas resection doubles the mortality rate and occurs in 30% of operations. Currently used fibrin-based sealants are not resistant to pancreatic juice, failing to reduce fistula formation and mortality. Consequently, an effective sealant for use after pancreatectomy is an urgent medical need. The Adhesys technology exhibits the required properties for such use, including its resistance to pancreatic juice and its remainder on the wound site for long enough to extend over the period of natural wound healing. Consequently, the VIVO technology meets the requirements for the development of an adhesive to seal pancreatic resection margins after pancreatectomy in order to reduce postoperative fistula formation.
Also the CUTIS technology can be developed to meet clinical needs in a variety of new application areas. Potential innovations with the technology include:
- household and sports applications
- treatments for chronic wounds and diabetic ulcers
- applications for emergency situations.
 Seufferlein T, Porzner M, Heinemann V, Tannapfel A, Stuschke M, Uhl W: Clinical practice guideline: Ductal pancreatic adenocarcinoma—surgery, pathology work-up, and neoadjuvant, adjuvant and palliative treatments, Dtsch Arztebl Int 2014; 111(22): 396-402.
 World Health Organization, World Cancer Report 2014. Chapter 5-7, ISBN: 9283204298.